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the utilization of substituted imidazoles in the treatment 
of epilepsy was brought in with the synthesis of Denzimol 
(I)[4] and Nafimidone (II),[5] respectively [Figure 1]. A 
sound understanding of the structural requirements of 
imidazoles for antiepileptic activity is important in guiding 
and optimizing the drug design efforts. 
Comparative molecular field analysis (CoMFA) and 
Comparative molecular similarity indices analysis 
(CoMSIA) are powerful tools to build and design an 
activity model (QSAR), for a given set of molecules in 
a rational drug design and related applications.[6,7] The 
CoMFA methodology is based on the assumption that the 
changes in the biological activity correlate with the changes 
in the steric and electrostatic fields of the molecules.[8] 
The CoMSIA[8,9] method was introduced by Klebe and 
INTRODUCTION
Epilepsy is a chronic and often progressive disorder 
characterized by the periodic and unpredictable occurrence 
of epileptic seizures, which are caused by an abnormal 
discharge of cerebral neurons.[1] There is a continuing 
demand for new anticonvulsant agents, as it has not been 
possible to control every kind of seizure with the currently 
available antiepileptic drugs. Moreover, the current therapy 
of epilepsy, with modern antiepileptic drugs, is associated 
with dose-related side effects, chronic toxicity, and 
teratogenic effects.[2,3] Therefore, new antiepileptic drug 
development, with approved therapeutic properties, is an 
important challenge for medicinal chemists.
Hydantoin was used as an antiepileptic from the 1860s, but 
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A three-dimensional quantitative structure-activity relationship (3D QSAR) of 44 structurally and functionally 
diverse series of 1- (Naphthylalkylimidazoles) as antiepileptic agents was studied using the Comparative molecular 
similarity indices analysis (CoMSIA) method. A training set containing 34 molecules served to establish the 
models. The optimum CoMSIA model obtained for the training set were all statistically significant, with cross-
validated coefficients (q2) of 0.725 and conventional coefficients (r2
ncv) of 0.998. The predictive capacities of the 
model were successfully validated by using a test set of 10 molecules that were not included in the training set. 
CoMSIA model (Model 1) obtained from the hydrophobic and Hbond acceptor field was found to have the best 
predictivity, with a predictive correlation coefficient (r2
pred) of 0.67. The information obtained from this 3D-QSAR 
model can be used to guide the development of imidazoles as novel antiepileptic agents.
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includes additional molecular fields, such as, the lipophillic 
and hydrogen bond potential. CoMSIA introduces the 
Gaussian function for the distance dependence between 
the molecular atoms and the probe atoms, in order to 
avoid some of the inherent deficiencies arising from the 
Lennard-Jones and Coulomb potential functional forms. 
In CoMSIA, five different similarity fields, namely, steric, 
electrostatic, hydrophobic, hydrogen bond donor, and 
hydrogen bond acceptor fields were calculated. These fields 
were selected to cover the major contributions to ligand 
binding and have several advantages over CoMFA, such 
as, development of a more robust 3D QSAR model, with 
no arbitrary cut-offs and more intuitively interpretable 
contour maps. This article describes the Comparative 
Molecular Similarity Indices Analysis (CoMSIA) of a series 
of 1-(Naphthylalky1)-1H–imidazole analogs [Table 1]. 
On the basis of the CoMSIA model generated by us we 
attempted to elucidate a structure-activity relationship to 
provide useful information for the design of more selective 
and potent antiepileptic imidazole analogs. 
MATERIALS AND METHODS
Data set 
Reported data on a series of 44 1-(Naphthylalky1)-1H –
imidazole derivatives[5] were used [Table 1]. The ED 50 data 
for a Maximal Electroshock induced seizure (MES test) 
were used for QSAR analysis, as a dependent parameter, 
after converting the reciprocal of the logarithm of ED50 
(p ED50) values. ED50 was the dose of a drug that was 
pharmacologically effective for 50% of the population 
exposed to the drug. The total set of the imidazole analogs 
were segregated into the training set and the test set, in 
an approximately 4:1 ratio, each containing 34 and 10 
molecules, respectively. The division was made at random 
with bias given to structural diversity in both the training 
set and the test set.
Molecular modeling 
The CoMSIA studies reported herein were performed using 
Figure 1: Chemical structures of Denzimol (I) and Nafimidone (II)
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Table 1: Dataset used for CoMSIA analyses
Compound 
no.
Substituent ED50
a 
(mg/kg) A R Napthyl N
1 O - 2 1 15
2 O 6-Cl 2 1 51
3 O 6-CH3 2 1 24
4 O 6-C2H5 2 1 12
5 O 6,7-(CH3)2 2 1 25
6 O 6-OCH3 2 1 31
7 O 1-OCH3 2 1 23
8 O 7-CH3 1 1 22
9 O 7-C2H5 1 1 13
10 O 6,7-(OCH3)2 1 1 79
11 OCH2CH2O - 2 1 12
12 OCH2C(CH3)2 
CH2O
- 2 1 26
13 (OCH3)2 - 2 1 40
14 S(CH2)3S - 2 1 65
15 SCH2CH2S - 1 1 26
16 (SCH3)2 - 2 1 32
17 (SC2H5)2 - 2 1 35
18 (S-i-C3H7)2 - 2 1 86
19 (SC6H5)2 - 2 1 60
20 (SCH2C6H5)2 - 2 1 100
21 OCH2CH2O - 2 2 35
22 H2 - 2 1 22
23 H2 - 2 0 25
24 OH - 2 1 74
25 OH - 1 1 34
26 OCH3 - 2 1 10
27 OC2H5 - 2 1 11
28 OCH3 - 1 1 19
29 p-OC6H4Cl - 2 1 46
30 o-OC6H4CH3 - 2 1 33
31 OCOC2H5 - 2 1 23
32 SCH3 - 2 1 37
33 OH - 2 2 13
34 OCH3 - 2 2 11
35* O 4-CH(CH3)2 1 1 28
36* O(CH2)3O - 2 1 17
37* OCH(CH3)
(CH2)2O
- 2 1 19
38* OCH2CH2O - 1 1 19
39* SCH2CH2S - 2 1 26
40* (S-n-C3H7)2 - 2 1 100
41* (S-i-C4H9)2 - 2 1 100
42* O - 2 2 10
43* O-n-C4H9 - 1 1 16
44* OCOC6H5 - 2 1 19
*Test set molecules (25%), aED50 is Median Effective ConcentrationGanguly and Mishra. J Young Pharm. 2010;2(4): 388-393
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SYBYL 7.1[10] molecular modeling software installed on a 
Dell computer, with Red Hat Linux Enterprise Version 3.0 
(with 512 MB of memory). All the compounds were built 
from fragments in the SYBYL database. Each structure was 
fully geometry-optimized using the standard Tripos force 
field with a distance-dependent dielectric function, until 
a Root Mean Square (RMS) deviation of 0.001 kcal mol-1 
Å-1 was achieved. All the compounds were then subjected 
to simulated dynamic annealing with 100 cycles. The least 
energy conformations were selected for each compound 
and further energy minimized using Powell (100 iterations) 
and Conjugation gradient (10,000 iterations) methods. 
Gasteiger–Huckel charges were computed for all molecules 
after energy minimization.
Alignment 
Molecular conformation and orientation is one of the most 
sensitive input areas in 3D-QSAR studies. In the present 
study, superimposition of the molecules was carried out 
by DATABASE ALIGNMENT, using compound 26 
[Table 1] as a template structure. The molecules were 
aligned to the template molecule by using a common 
substructure labeled with *, as shown in Figure 2. The 
aligned molecules are shown in Figure 3.
CoMSIA interaction energy calculation[8]
In CoMSIA field energy calculation, the probe atom with 
radius 1 Å, charge + 1.0, hydrogen bond donating + 1.0, 
hydrogen bond accepting + 1.0, and hydropobicity + 
1.0 were used. An attenuation factor of 0.3 was used to 
estimate the steric, electrostatic, hydrophobic, hydrogen 
bond donor, and acceptor fields in CoMSIA.
Partial least square (PLS) analysis[11]
PLS regression technique is especially useful in common 
cases where the number of descriptors (independent 
variables) is comparable to or greater than the number of 
compounds (data points) and / or there exist other factors 
leading to correlations between variables. The column 
filtering value(s) were set to 2.0 kcal/mol, to improve the 
signal-to-noise ratio. Cross-validations were performed by 
the Leave-One-Out (LOO) procedure, to determine the 
optimum number of components (N). The cross-validated 
r2 that resulted in optimum number of components and 
lowest standard error of prediction were considered for 
further analysis. The final analysis was performed to 
calculate conventional r2 using the optimum number of 
components. Bootstrapping analysis for 100 runs was 
performed.
Predictive correlation coefficient[8,12]
The predictive power of the model, predictive correlation 
coefficient (r2
pred), based on molecules of the test set was 
calculated by the following equation.
r2
pred = (SD – PRESS) / SD
Where SD is the sum of the squared deviations between 
the biological activities of each molecule and the mean 
activity of the training set of molecules and PRESS is the 
sum of squared deviations between the predicted and actual 
activity values for every molecule in the test set.
RESULTS 
Based on the predictive correlation coefficient (r2
pred = 
0.67), the combination of hydrophobic and hydrogen bond 
Figure 2: Template molecule 26 with common substructure labeled 
with *
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Figure 3: Alignment of training set moleculesCoMSIA studies of imidazoles with antiepileptic activity
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acceptor fields in CoMSIA gave the best results (Model 1), 
giving a cross-validation correlation coefficient of 0.725 
and a conventional correlation coefficient of 0.998. The 
other combinations such as (i) steric, hydrophobic, and 
hydrogen bond acceptor fields (Model 2) and (ii) steric and 
hydrogen bond acceptor fields (Model 3) in CoMSIA also 
gave statistically significant models. All other combinations 
in CoMSIA gave statistically insignificant results   
[Figure 4]. Model 1 of CoMSIA was used for final analysis 
and predictions. A high r2 value of 0.998 during 100 runs 
of bootstrapped analysis further supported the statistical 
validity of the model. The results of PLS analysis are 
shown in Table 2. A plot of predicted (CoMSIA) versus 
the actual activity for the training set molecules is shown in 
Figure 5. Figure 4 represents the plot of the cross-validated 
correlation coefficient versus all the CoMSIA models. The 
actual and predicted activity of training and test set for all 
CoMSIA models are given in Tables 3 and 4, respectively. 
The 3DQSAR contour maps revealing the contribution of 
the CoMSIA fields is shown in Figure 6. The contributions 
of the hydrophobic and hydrogen bond acceptor fields of 
CoMSIA are in the ratio 4:6 [Table 2]. 
DISCUSSION
Considering the hydrophobic contours of CoMSIA 
(Model 1), the yellow(Y) contours denote regions 
where hydrophobic groups are favored, while white (W) 
contours indicate regions where hydrophilic groups can 
be incorporated. Figure 6a shows that the 2-methoxyethyl 
substituent at the first position of the imidazole nucleus 
Table 2: Statistics of CoMSIA models
Parameters HA (Model 1) CoMSIA
SHA (Model 2) SA (Model 3)
r2cv  0.725 0.682 0.661
r2ncv  0.998 0.997 0.995
SEE  0.013 0.016 0.020
F  3111.632 1859.435 1235.770
r2bs  0.998 0.998 0.996
r2pred  0.6671 0.1351 -0.0981
Component  5 5 5
Fraction
Steric  - 0.211 0.352
Electrostatic  - - -
Hydrophobic  0.438 0.311 -
Acceptor  0.562 0.459 0.648
Donor - - -
r2
cv: Cross-validated correlation coefficient, N: Number of components, 
r2: Conventional correlation coefficient, SEE: Standard error of estimate, PRESS: 
Predicted residual sum of squares of test set molecules, r2
pred: Predictive correlation 
coefficient, r2
bs: Correlation coefficient after 100 runs of bootstrapping analysis, S: 
Steric field, H: Hydrophobic field, A: hydrogen bond acceptor field
Table 3: Experimental and predicted activities of 
compounds in training set
Structure no. Actual activity 
(pED50
b)
CoMSIA (Predicted activity)
Model 1 
(HA) 
Model 2 
(SHA) 
Model 3 
(SA) 
1 1.17613 1.16640 1.17216 1.16571
2 1.70757 1.72051 1.70685 1.68225
3 1.38021 1.39070 1.40259 1.35321
4 1.07919 1.06169 1.08657 1.08432
5 1.39794 1.40956 1.38229 1.40084
6 1.49136 1.50355 1.49943 1.50450
7 1.36172 1.36496 1.38572 1.40760
8 1.34242 1.34513 1.36913 1.36773
9 1.11394 1.12009 1.11628 1.11148
10 1.89762 1.90523 1.90756 1.92671
11 1.07919 1.08055 1.07728 1.09711
12 1.41497 1.41269 1.39408 1.40669
13 1.60205 1.59645 1.58794 1.59678
14 1.81291 1.82170 1.81479 1.81102
15 1.41497 1.41112 1.42958 1.44960
16 1.50514 1.52417 1.53251 1.51736
17 1.54406 1.53367 1.52096 1.53887
18 1.93449 1.90724 1.91251 1.89186
19 1.77810 1.77306 1.77659 1.7852
20 2.00000 2.01645 2.01997 2.00159
21 1.54406 1.54296 1.53474 1.53512
22 1.34242 1.33465 1.33744 1.33597
23 1.39794 1.41050 1.40762 1.41176
24 1.86923 1.83959 1.84527 1.85428
25 1.53147 1.51507 1.50896 1.53133
26 1.00000 0.99129 0.99811 1.00204
27 1.04139 1.04901 1.03550 1.04202
28 1.27875 1.27785 1.29609 1.27773
29 1.66270 1.67162 1.67825 1.68669
30 1.51851 1.51225 1.51949 1.51104
31 1.36172 1.36580 1.34753 1.34561
32 1.56820 1.57128 1.56144 1.55484
33 1.11396 1.10643 1.11236 1.10198
34 1.04143 1.05256 1.02817 1.01496
pED50
b = -LogED50
Table 4: Experimental and predicted activities of 
compounds in test set
Structure no. Actual activity 
(pED50
b)
CoMSIA (Predicted activity)
Model 1 
(HA)
Model 2 
(SHA)
Model 3  
(SA) 
35* 1.44710 1.35280 1.23811 1.44710
36* 1.23045 1.09328 1.11691 0.90422
37* 1.27875 1.04060 1.00268 0.98745
38* 1.27875 1.15136 1.04132 0.87593
39* 1.41497 1.44695 1.30756 1.27258
40* 2.00000 1.69197 1.42497 1.47527
41* 2.00000 1.70970 1.48629 1.39003
42* 1.00000 0.99926 1.15160 1.17321
43* 1.20411 0.984424 1.20258 1.03100
44* 1.27875 1.32600 1.48527 1.19955
pED50
b = -LogED50Ganguly and Mishra. J Young Pharm. 2010;2(4): 388-393
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Figure 5: Plot of predicted versus actual pED50 values of molecules 
for CoMSIA Model 1 (HA)
Figure 4: Plot of r2 cross-validated versus 31 different CoMSIA models
Figure 6: The CoMSIA hydrophobic (a) and hydrogen bond acceptor (b) contour maps. One of the most active molecules, 26, is shown in the 
background. Yellow (Y) is a hydrophobically favored region, white (W) hydrophobically disfavored region, magenta (M) color is a hydrogen 
acceptor favored region, cyan (C) color is a hydrogen acceptor disfavored region
a b
is embedded in a big yellow (Y) contour, indicating that 
the substitution with hydrophobic groups will increase the 
activity. The second position of the imidazole ring and 
the eighth position of the naphthalene ring are embedded 
in white (W) contour, indicating that introduction of 
hydrophilic groups at these positions will increase the 
activity. Similarly the third position of the napthyl group is 
surrounded by a white (W) contour indicating that addition 
of hydrophobic groups will decrease the activity. In the 
H-bond acceptor field [Figure 6b], magenta (M) contours 
represent the favored region, while red (R) contours show 
the disfavored region. The second position of the imidazole 
ring is embedded in big red (R) contour, indicating that 
substitution with the hydrogen bond donor group may 
increase the activity, while the fourth and fifth position 
of imidazole is embedded in large magenta (M) contours, 
indicating introduction of hydrogen bond acceptor groups 
may result in increased activity. The 2-methoxy group 
attached to the CH2CH2 side chain at the first position of 
the imidazole nucleus is embedded in a red (R) contour, 
indicating that activity may increase if this position is 
substituted with hydrogen bond donor groups. 
CONCLUSION
The CoMSIA analysis has been successfully applied to 
a series of 1-(Naphthylalky1)-1H –imidazole derivatives 
with anticonvulsant activity. The CoMSIA model (Model 
1) was very well validated both internally and externally 
and proved to be the best of all the models developed. 
The robustness of the HA model was verified by the 
bootstrapping method. This model with a combination 
hydrophobic and H-bond acceptor fields (HA) indicates 
that hydrophobic and hydrogen bond acceptor groups CoMSIA studies of imidazoles with antiepileptic activity
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may be important for the design of more potent imidazole 
analogs, as antiepileptic agents. Results of this study may 
be utilized for future drug design studies and synthesis of 
more potent antiepileptic agents with the arylalkylimidazole 
scaffold.
ACKNOWLEDGMENTS
The authors are grateful for the financial aid in the form of a 
Fellowship by the All India Council for Technical Education, 
New Delhi, India.
REFERENCES 
1.  Loscher W. New visions in the pharmacology of anticonvulsant. Eur J 
Pharmacol 1998;342:1-13.
2.  Wilk IJ. Chemical aspects of anticonvulsant drugs. J Chem Educ 
1957;34:199.
3.  Mattson RH. Efficacy and adverse effects of established and new 
antiepileptic drugs. Epilepsia 1995;36:S13-26.
4.  Dante N, Tajana A, Leonardi A, Renzo P, Portioli F, Jose M, et al. Synthesis 
and anticonvulsant activity of N-(Benzoylalky1) imidazoles and N-(ω-
Phenyl-ω-hydroxyalky1) imidazoles. J Med Chem 1981;24:721-31.
5.  Walker KA, Wallach MB, Hirschfield DR. 1-(Naphthylalky1)-1H imidazole 
derivatives, a new class of anticonvulsant agents. J Med Chem 1981;24:67-74. 
6.  Kim KH. Comparative molecular field analysis (CoMFA). In: Dean PM, 
editor. Molecular Similarity in Drug Design. London: Blackie Academic 
and Professional; 1995. p. 291-331.
7.  Bohacek RS, McMartin CK. Definition and display of steric, hydrophobic 
and hydrogen bonding properties of ligand binding sites in proteins using 
Lee and Richards’s accessible surface: Validation of high-resolution graphical 
tool for drug design. J Med Chem 1992;35:1671-84. 
8.  Chakroborti AK, Gopalakrishnan B, Sobhia ME, Malde AK. 3D-QSAR 
studies of indole derivatives as phosphodiesterase IV inhibitors. Eur J Med 
Chem 2003;38:975-82.
9.  Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a 
comparative molecular field analysis (CoMFA) of drug molecules to 
correlate and predict their biological activity. J Med Chem 1994;37:4130-46. 
10.  SYBYL molecular modeling system, Version 7.1. St. Louis, MO: Tripos 
Associate 2010.
11.  Hokuldsson A. PLS regression methods. J Chemo Metrics 1988;2:211-28.
12.  Ganguly S, Prasanthi N. 3D QSAR studies of NAIMS analogs as anti-HIV 
agents. J Young Pharmacists 2009;1:251-8.
Source of Support: Nil, Conflict of Interest: None declared.